share_log

BioNTech | 6-K: Report of foreign private issuer (related to financial reporting)

BioNTech | 6-K: Report of foreign private issuer (related to financial reporting)

BioNTech | 6-K：外国发行人报告（业绩相关）
美股SEC公告 ·  2024/08/05 18:37

Moomoo AI 已提取核心信息

BioNTech reported Q2 2024 revenues of €128.7 million, down from €167.7 million year-over-year, with a net loss of €807.8 million. The company invested €525.6 million in R&D during Q2, with approximately 90% focused on non-COVID-19 activities, primarily oncology. The financial position remains strong with €18.5 billion in cash and investments as of June 30, 2024.The company achieved significant clinical milestones, including positive data from multiple mRNA cancer vaccine trials. Notably, the Phase 2 trial of BNT111 met its primary efficacy endpoint in melanoma patients. BioNTech also launched its updated variant-adapted COVID-19 vaccine in the EU and received UK approval, while initiating a rolling sBLA with the U.S. FDA.BioNTech reiterated its 2024 revenue guidance of €2.5-3.1 billion, expecting the majority of revenues in Q4. The company continues to advance its oncology pipeline with multiple clinical trials, including combinations of novel therapeutics, while expanding manufacturing capabilities through strategic partnerships like the €145 million CEPI collaboration for vaccine production in Rwanda.
BioNTech reported Q2 2024 revenues of €128.7 million, down from €167.7 million year-over-year, with a net loss of €807.8 million. The company invested €525.6 million in R&D during Q2, with approximately 90% focused on non-COVID-19 activities, primarily oncology. The financial position remains strong with €18.5 billion in cash and investments as of June 30, 2024.The company achieved significant clinical milestones, including positive data from multiple mRNA cancer vaccine trials. Notably, the Phase 2 trial of BNT111 met its primary efficacy endpoint in melanoma patients. BioNTech also launched its updated variant-adapted COVID-19 vaccine in the EU and received UK approval, while initiating a rolling sBLA with the U.S. FDA.BioNTech reiterated its 2024 revenue guidance of €2.5-3.1 billion, expecting the majority of revenues in Q4. The company continues to advance its oncology pipeline with multiple clinical trials, including combinations of novel therapeutics, while expanding manufacturing capabilities through strategic partnerships like the €145 million CEPI collaboration for vaccine production in Rwanda.
BioNTech报告2024年第二季度营业收入为12870万欧元，同比下降16770万欧元，净损失为80780万欧元。该公司在第二季度投资了52560万欧元用于研发，其中约90%集中在非COVID-19活动，主要是肿瘤学。截至2024年6月30日，公司的财务状况仍然强劲，现金和投资总额为185亿欧元。该公司实现了重要的临床里程碑，包括多项mRNA癌症生物-疫苗试验的积极数据。值得注意的是，BNT111的第二阶段试验在黑色素瘤患者中达到了主要有效性终点。BioNTech还在欧盟推出了更新版适应变种的COVID-19生物-疫苗，并获得了英国的批准，同时启动了与美国FDA的滚动生物-疫苗申请。BioNTech重申其2024年营业收入指导为25-31亿欧元，预计大部分收入将在第四季度实现。该公司继续推进其肿瘤学产品线，进行多项临床试验，包括新型治疗的组合，同时通过与CEPI的14500万欧元合作扩展其制造能力，以在卢旺达进行生物-疫苗生产。
BioNTech报告2024年第二季度营业收入为12870万欧元，同比下降16770万欧元，净损失为80780万欧元。该公司在第二季度投资了52560万欧元用于研发，其中约90%集中在非COVID-19活动，主要是肿瘤学。截至2024年6月30日，公司的财务状况仍然强劲，现金和投资总额为185亿欧元。该公司实现了重要的临床里程碑，包括多项mRNA癌症生物-疫苗试验的积极数据。值得注意的是，BNT111的第二阶段试验在黑色素瘤患者中达到了主要有效性终点。BioNTech还在欧盟推出了更新版适应变种的COVID-19生物-疫苗，并获得了英国的批准，同时启动了与美国FDA的滚动生物-疫苗申请。BioNTech重申其2024年营业收入指导为25-31亿欧元，预计大部分收入将在第四季度实现。该公司继续推进其肿瘤学产品线，进行多项临床试验，包括新型治疗的组合，同时通过与CEPI的14500万欧元合作扩展其制造能力，以在卢旺达进行生物-疫苗生产。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    2seventy bio
    TSVT
    -- 4.950
    Syros Pharmaceuticals
    SYRS
    -- 0.1360
    Dogwood Therapeutics
    DWTX
    -- 11.130
    Camp4 Therapeutics
    CAMP
    -- 5.490
    Anebulo Pharmaceuticals
    ANEB
    -- 1.390
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    特斯拉绩后巨震，后市你怎么看？
    特斯拉2024年Q4营收257.1亿美元，同比增长2%，不及预期。Cybercab计划2026年投产，预计车辆业务将于2025年恢复增长。面对特朗普回归，特斯拉股价能否在2025年继续攀升？ 展开
    TSLA财报预告：通过猜测开盘价来获取奖励！